Recombinant activated factor VII for refractory bleeding during pediatric spinal tumor surgery: A case report
Bleeding complications constitute a particular challenge in neurosurgical procedures especially in children and may be life-threatening. We report the case of a 5-month-old boy to whom recombinant activated factor VII was given at doses of 90 μg/kg of body weight for the control of refractory perioperative bleeding during spinal neurofibromas surgery. Conventional treatment with fresh-frozen plasma, platelet concentrates, and fibrinogen concentrate failed to control hemorrhage. Recombinant activated factor administration resulted in decreased bleeding, hemodynamic stabilization, and improved surgical hemostasis.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.